Pacific Biosciences of California (NASDAQ:PACB), According to the latest information the short interest in Pacific Biosciences of California, Inc. shot up by 1.4% or 200,072 shares. The final shorts are 20.1% of the total floated shares. The positions increased from 14,721,603 shares on May 31,2016 to 14,921,675 on June 15,2016. According to the per-day average trading of 2,518,483 shares, the days to cover are 6. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Pacific Biosciences of California (NASDAQ:PACB): The stock opened at $8.29 on Friday but the bulls could not build on the opening and the stock topped out at $8.47 for the day. The stock traded down to $8.06 during the day, due to lack of any buying support eventually closed down at $8.13 with a loss of -5.47% for the day. The stock had closed at $8.60 on the previous day. The total traded volume was 3,593,200 shares.
The company shares have rallied 42.38% from its 1 Year high price. On Dec 31, 2015, the shares registered one year high at $14.00 and the one year low was seen on Sep 30, 2015. The 50-Day Moving Average price is $9.18 and the 200 Day Moving Average price is recorded at $9.79.
Pacific Biosciences of California (NASDAQ:PACB) has tumbled 5.9% during the past week and has dropped 11.25% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 4.34%. Pacific Biosciences of California (NASDAQ:PACB) has underperformed the index by 8.56% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Pacific Biosciences of California Inc. designs, develops and manufactures the PacBio RS II Sequencing System to help scientists resolve genetically complex problems. Based on the Companys Single Molecule, Real-Time (SMRT) technology, its products enable de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms and find genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA (deoxyribonucleic acid) base modification identification to help characterize epigenetic regulation and DNA damage. SMRT enables single molecule, real-time detection of biological processes. Based on its SMRT technology, the Company introduced the PacBio RS II System to address many of the limitations.